Our Pipeline

Our goal is to transform the prevention and treatment of infectious diseases and cancers to significantly improve the lives of patients by developing and commercializing a new class of ‘‘off-the-shelf’’ immunotherapeutics.

We are leveraging our modular arenavirus platform to develop the following product candidates for multiple infectious diseases and cancers - the efficacy of our TheraT®* and VaxWave®* platforms is being tested all across our pipeline:

Compound
Antigen
Target
Pre-ClinicalPre.
Phase1Ph1.
Phase2Ph2.
Phase3Ph3.
Anticipated Milestones
Global Rights
HB-101
(VaxWave®)
gB/pp65
CMV
Preliminary data
H1 2020
HBV
Therapy
Undisclosed
HBV
Gilead Investors Biotech
HIV
Therapy
Undisclosed
HIV
Gilead Investors Biotech
HB-201
(TheraT® LCMV)
E6/E7
HPV16+ Cancer
IND H1 2019
Data late 2020/
early 2021
HB-202
(TheraT® PICV/
TheraT® LCMV)
E6/E7
HPV16+ Cancer
IND H1 2020
Data mid-2021
HB-301
(TheraT®)
PSA/PSMA/PAP
Prostate Cancer
Infectious
Oncology

*Registered in Europe; Pending in the US